Very interestingly, our combined spectral biomarker appears to outperform the classification performance of two widely used circulating HCC markers—namely, AFP and PIVKA-II—measured on the same group of subjects, a result that deserves a dedicated study based on a larger sample size. This evidence concerns the gene AFP and hepatocellular carcinoma.